Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial

作者：Joensuu H^*; Sailas L; Alanko T; Sunela K; Huuhtanen R; Utriainen M; Kokko R; Bono P; Wigren T; Pyrhonen S; Turpeenniemi Hujanen T; Asola R; Leinonen M; Hahka Kemppinen M; Kellokumpu Lehtinen P

来源：Annals of Oncology, 2010, 21(5): 968-973.

DOI：10.1093/annonc/mdp397

• advanced stage
• breast cancer
• chemotherapy
• docetaxel
• gemcitabine
• randomised clinical trial

Patients and methods: Women diagnosed with advanced breast cancer were randomly allocated to receive 3-weekly docetaxel (group D) or 3-weekly docetaxel alternating with 3-weekly gemcitabine (group D/G) until treatment failure as first-line chemotherapy. The primary end point was TTF.
Results: Two hundred and thirty-seven subjects were assigned to treatment (group D, 115; group D/G, 122). The median TTF was 5.6 and 6.2 months in groups D and D/G, respectively (hazard ratio 0.85, 95% confidence interval 0.63-1.16; P = 0.31). There was no significant difference in time-to-disease progression, survival, and response rate between the groups. When adverse events were evaluated for the worst toxicity encountered during treatment, there was little difference between the groups, but when they were assessed per cycle, alternating treatment was associated with fewer severe (grade 3 or 4) adverse effects (P = 0.013), and the difference was highly significant for cycles when gemcitabine was administered in group D/G (P < 0.001).
Conclusion: The alternating regimen was associated with a similar TTF as single-agent docetaxel but with fewer adverse effects during gemcitabine cycles.

• 出版日期2010-5